> top > docs > PubMed:809441 > annotations

PubMed:809441 JSONTXT

Annnotations TAB JSON ListView MergeView

Test-Species-PubTator

Id Subject Object Predicate Lexical cue resolved_to
4 22-40 Chemical denotes glycosphingolipids MESH:D006028
5 63-68 Species denotes human 9606
6 75-82 Species denotes patient 9606
7 88-103 Disease denotes Fabry's disease MESH:D000795
38 106-119 Chemical denotes 6-2H2]Glucose -
39 198-215 Chemical denotes glycosylceramides -
40 253-260 Species denotes patient 9606
41 266-281 Disease denotes Fabry's disease MESH:D000795
42 364-382 Chemical denotes glycosphingolipids MESH:D006028
43 443-474 Chemical denotes tetra-0-acetyl methyl glycoside -
44 550-565 Chemical denotes [6,6-2H2]hexose -
45 629-645 Chemical denotes [6,6-2H2]glucose -
46 904-911 Chemical denotes glucose MESH:D005947
47 966-982 Chemical denotes [6,6-2H2]glucose -
48 1084-1100 Chemical denotes [6,6-2H2]glucose -
49 1117-1133 Chemical denotes glucosylceramide MESH:D005963
50 1135-1140 Chemical denotes GL-la MESH:D005963
51 1253-1258 Chemical denotes lipid MESH:D008055
52 1395-1400 Chemical denotes GL-la MESH:D005963
53 1431-1446 Chemical denotes [6,6-2H2]hexose -
54 1452-1468 Chemical denotes lactosylceramide MESH:C009744
55 1470-1516 Chemical denotes galactosyl-(beta1 leads to 4)-glucosylceramide -
56 1543-1548 Disease denotes Fabry MESH:D000795
57 1549-1556 Species denotes patient 9606
58 1596-1614 Chemical denotes trihexosylceramide MESH:D014281
59 1616-1693 Chemical denotes galactosyl-(alpha1 leads to 4)-galactosyl-(beta1 leads to 4)-glucosylceramide -
60 1695-1700 Chemical denotes GL-3a -
61 1755-1770 Chemical denotes [6,6-2H2]hexose -
62 1828-1833 Chemical denotes GL-3a -
63 1843-1848 Disease denotes Fabry MESH:D000795
64 1849-1856 Species denotes patient 9606
65 2026-2031 Disease denotes Fabry MESH:D000795
66 2032-2039 Species denotes patient 9606
67 2105-2123 Chemical denotes glycosphingolipids MESH:D006028

Test-Species-PubDictionaries

Id Subject Object Predicate Lexical cue db_id
T1 63-68 OrganismTaxon denotes human 9606
T2 75-82 OrganismTaxon denotes patient 9606
T3 253-260 OrganismTaxon denotes patient 9606
T4 1549-1556 OrganismTaxon denotes patient 9606
T5 1849-1856 OrganismTaxon denotes patient 9606
T6 2032-2039 OrganismTaxon denotes patient 9606

Test-Species-PubDictionaries-PubMedBERT

Id Subject Object Predicate Lexical cue db_id
T1 56-62 Species denotes normal 2974449
T2 63-68 Species denotes human 9606
T3 75-82 Species denotes patient 9606
T4 253-260 Species denotes patient 9606
T5 443-448 Species denotes tetra 1310384|42554
T7 823-831 Species denotes constant 142498
T8 1543-1548 Species denotes Fabry 342562
T9 1549-1556 Species denotes patient 9606
T10 1843-1848 Species denotes Fabry 342562
T11 1849-1856 Species denotes patient 9606
T12 2026-2031 Species denotes Fabry 342562
T13 2032-2039 Species denotes patient 9606

GlyCosmos6-Glycan-Motif-Image

Id Subject Object Predicate Lexical cue image
T1 112-119 Glycan_Motif denotes Glucose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G15021LG
T2 638-645 Glycan_Motif denotes glucose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G15021LG
T3 904-911 Glycan_Motif denotes glucose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G15021LG
T4 975-982 Glycan_Motif denotes glucose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G15021LG
T5 1093-1100 Glycan_Motif denotes glucose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G15021LG
T6 1117-1133 Glycan_Motif denotes glucosylceramide https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G71142DF
T7 1452-1468 Glycan_Motif denotes lactosylceramide https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G84224TW|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G74621DY|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G20420WT
T10 1500-1516 Glycan_Motif denotes glucosylceramide https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G71142DF
T11 1677-1693 Glycan_Motif denotes glucosylceramide https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G71142DF
T12 1978-1994 Glycan_Motif denotes glucosylceramide https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G71142DF

Glycosmos6-GlycoEpitope

Id Subject Object Predicate Lexical cue
T1 1452-1468 http://www.glycoepitope.jp/epitopes/EP0078 denotes lactosylceramide

sentences

Id Subject Object Predicate Lexical cue
T1 0-104 Sentence denotes Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease.
T2 105-282 Sentence denotes [6-2H2]Glucose was used as a tracer for a comparative study on the metabolism of the neutral glycosylceramides in plasma of a control subject and a patient with Fabry's disease.
T3 283-487 Sentence denotes The incorporation of the tracer into the glucosyl and galactosyl moieties of the glycosphingolipids was measured by gas chromatography-mass spectrometry of the tetra-0-acetyl methyl glycoside derivatives.
T4 488-704 Sentence denotes Experiments on the precision and accuracy for measurements of [6,6-2H2]hexose in a sample demonstrated that incorporation of 0.2% or more of [6,6-2H2]glucose could be detected with a 95% confidence limit of +/-0.16%.
T5 705-871 Sentence denotes The labeled substrate (35g) was infused into each subject with a 5-g priming dose and the remainder administered at a constant rate of 3 g/hour over a 10-hour period.
T6 872-1059 Sentence denotes During the infusion, the plasma glucose of each subject attained a concentration of about 30% [6,6-2H2]glucose which diminished rapidly after the administration of substrate was complete.
T7 1060-1220 Sentence denotes A concentration of 0.8% [6,6-2H2]glucose was observed in glucosylceramide (GL-la) from plasma of both subjects between 48 and 72 hours after the infusion began.
T8 1221-1362 Sentence denotes The label disappeared from this lipid at a logarithmic rate and 0.2% or less of the molecules were labeled 9 days after the experiment began.
T9 1363-1591 Sentence denotes In contrast to the results with GL-la, the maximum incorporation of [6,6-2H2]hexose into lactosylceramide (galactosyl-(beta1 leads to 4)-glucosylceramide) was 2-fold higher in the Fabry patient (1.6%) than in the control (0.8%).
T10 1592-1887 Sentence denotes The trihexosylceramide (galactosyl-(alpha1 leads to 4)-galactosyl-(beta1 leads to 4)-glucosylceramide, GL-3a) from plasma of the control reached a maximum of 0.4% [6,6-2H2]hexose in both the glucosyl and galactosyl moieties whereas the GL-3a from the Fabry patient was not significantly labeled.
T11 1888-2081 Sentence denotes The maximal labeling of the GL-4a fraction (N-acetyl-galactosaminyl-galactosyl-galactosyl-glucosylceramide) was slightly depressed in the Fabry patient (0.4%) as compared to the control (0.7%).
T12 2082-2223 Sentence denotes Turnover times for the glycosphingolipids of plasma were calculated to be from 4 to 8 days and the turnover rates were from 1 to 6 mumol/day.
T1 0-104 Sentence denotes Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease.
T2 105-282 Sentence denotes [6-2H2]Glucose was used as a tracer for a comparative study on the metabolism of the neutral glycosylceramides in plasma of a control subject and a patient with Fabry's disease.
T3 283-487 Sentence denotes The incorporation of the tracer into the glucosyl and galactosyl moieties of the glycosphingolipids was measured by gas chromatography-mass spectrometry of the tetra-0-acetyl methyl glycoside derivatives.
T4 488-704 Sentence denotes Experiments on the precision and accuracy for measurements of [6,6-2H2]hexose in a sample demonstrated that incorporation of 0.2% or more of [6,6-2H2]glucose could be detected with a 95% confidence limit of +/-0.16%.
T5 705-871 Sentence denotes The labeled substrate (35g) was infused into each subject with a 5-g priming dose and the remainder administered at a constant rate of 3 g/hour over a 10-hour period.
T6 872-1059 Sentence denotes During the infusion, the plasma glucose of each subject attained a concentration of about 30% [6,6-2H2]glucose which diminished rapidly after the administration of substrate was complete.
T7 1060-1220 Sentence denotes A concentration of 0.8% [6,6-2H2]glucose was observed in glucosylceramide (GL-la) from plasma of both subjects between 48 and 72 hours after the infusion began.
T8 1221-1362 Sentence denotes The label disappeared from this lipid at a logarithmic rate and 0.2% or less of the molecules were labeled 9 days after the experiment began.
T9 1363-1591 Sentence denotes In contrast to the results with GL-la, the maximum incorporation of [6,6-2H2]hexose into lactosylceramide (galactosyl-(beta1 leads to 4)-glucosylceramide) was 2-fold higher in the Fabry patient (1.6%) than in the control (0.8%).
T10 1592-1887 Sentence denotes The trihexosylceramide (galactosyl-(alpha1 leads to 4)-galactosyl-(beta1 leads to 4)-glucosylceramide, GL-3a) from plasma of the control reached a maximum of 0.4% [6,6-2H2]hexose in both the glucosyl and galactosyl moieties whereas the GL-3a from the Fabry patient was not significantly labeled.
T11 1888-2081 Sentence denotes The maximal labeling of the GL-4a fraction (N-acetyl-galactosaminyl-galactosyl-galactosyl-glucosylceramide) was slightly depressed in the Fabry patient (0.4%) as compared to the control (0.7%).
T12 2082-2223 Sentence denotes Turnover times for the glycosphingolipids of plasma were calculated to be from 4 to 8 days and the turnover rates were from 1 to 6 mumol/day.

GlyCosmos6-Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 112-119 https://glytoucan.org/Structures/Glycans/G15021LG denotes Glucose
T2 638-645 https://glytoucan.org/Structures/Glycans/G15021LG denotes glucose
T3 904-911 https://glytoucan.org/Structures/Glycans/G15021LG denotes glucose
T4 975-982 https://glytoucan.org/Structures/Glycans/G15021LG denotes glucose
T5 1093-1100 https://glytoucan.org/Structures/Glycans/G15021LG denotes glucose
T6 1117-1133 https://glytoucan.org/Structures/Glycans/G71142DF denotes glucosylceramide
T7 1452-1468 https://glytoucan.org/Structures/Glycans/G20420WT denotes lactosylceramide
T8 1452-1468 https://glytoucan.org/Structures/Glycans/G74621DY denotes lactosylceramide
T9 1452-1468 https://glytoucan.org/Structures/Glycans/G84224TW denotes lactosylceramide
T10 1500-1516 https://glytoucan.org/Structures/Glycans/G71142DF denotes glucosylceramide
T11 1677-1693 https://glytoucan.org/Structures/Glycans/G71142DF denotes glucosylceramide
T12 1978-1994 https://glytoucan.org/Structures/Glycans/G71142DF denotes glucosylceramide

GlyCosmos15-Glycan

Id Subject Object Predicate Lexical cue image
T1 1452-1468 Glycan denotes lactosylceramide https://api.glycosmos.org/wurcs2image/latest/png/binary/G84224TW

mondo_disease

Id Subject Object Predicate Lexical cue mondo_id
T1 88-103 Disease denotes Fabry's disease http://purl.obolibrary.org/obo/MONDO_0010526
T2 266-281 Disease denotes Fabry's disease http://purl.obolibrary.org/obo/MONDO_0010526

Glycan-GlyCosmos

Id Subject Object Predicate Lexical cue image
T1 1452-1468 Glycan denotes lactosylceramide https://api.glycosmos.org/wurcs2image/latest/png/binary/G84224TW

GlyCosmos-GlycoEpitope

Id Subject Object Predicate Lexical cue glycoepitope_id
T1 1452-1468 http://purl.jp/bio/12/glyco/glycan#Glycan_epitope denotes lactosylceramide http://www.glycoepitope.jp/epitopes/EP0078

Organism-PubDic

Id Subject Object Predicate Lexical cue db_id
T1 63-68 Species denotes human 9606
T2 75-82 Species denotes patient 9606
T3 253-260 Species denotes patient 9606
T4 1549-1556 Species denotes patient 9606
T5 1849-1856 Species denotes patient 9606
T6 2032-2039 Species denotes patient 9606

Organism-PubTator

Id Subject Object Predicate Lexical cue db_id
5 63-68 Species denotes human 9606
6 75-82 Species denotes patient 9606
40 253-260 Species denotes patient 9606
57 1549-1556 Species denotes patient 9606
64 1849-1856 Species denotes patient 9606
66 2032-2039 Species denotes patient 9606

Organism-PubDic-Bert-9

Id Subject Object Predicate Lexical cue db_id
T1 63-68 Species denotes human 9606
T2 75-82 Species denotes patient 9606
T3 253-260 Species denotes patient 9606
T4 443-448 Species denotes tetra 1310384|42554
T6 823-831 Species denotes constant 142498
T7 1549-1556 Species denotes patient 9606
T8 1849-1856 Species denotes patient 9606
T9 2032-2039 Species denotes patient 9606

Organism-PubDic-Bert-8

Id Subject Object Predicate Lexical cue db_id
T1 56-62 Species denotes normal 2974449
T2 63-68 Species denotes human 9606
T3 75-82 Species denotes patient 9606
T4 253-260 Species denotes patient 9606
T5 443-448 Species denotes tetra 1310384|42554
T7 823-831 Species denotes constant 142498
T8 1543-1548 Species denotes Fabry 342562
T9 1549-1556 Species denotes patient 9606
T10 1843-1848 Species denotes Fabry 342562
T11 1849-1856 Species denotes patient 9606
T12 2026-2031 Species denotes Fabry 342562
T13 2032-2039 Species denotes patient 9606

Organism-Gold

Id Subject Object Predicate Lexical cue db_id
T1 63-68 Species denotes human 9606
T2 75-82 Species denotes patient 9606
T3 253-260 Species denotes patient 9606
T4 1549-1556 Species denotes patient 9606
T5 1849-1856 Species denotes patient 9606
T6 2032-2039 Species denotes patient 9606

GlyCosmos15-Taxon

Id Subject Object Predicate Lexical cue db_id
T1 63-68 Organism denotes human 9606
T2 75-82 Organism denotes patient 9606
T3 253-260 Organism denotes patient 9606
T4 1549-1556 Organism denotes patient 9606
T5 1849-1856 Organism denotes patient 9606
T6 2032-2039 Organism denotes patient 9606

GlyCosmos15-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 44-50 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T2 219-225 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T3 897-903 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T4 1147-1153 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T5 1707-1713 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T6 2127-2133 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969

GlyCosmos15-Sentences

Id Subject Object Predicate Lexical cue
T1 0-104 Sentence denotes Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease.
T2 105-282 Sentence denotes [6-2H2]Glucose was used as a tracer for a comparative study on the metabolism of the neutral glycosylceramides in plasma of a control subject and a patient with Fabry's disease.
T3 283-487 Sentence denotes The incorporation of the tracer into the glucosyl and galactosyl moieties of the glycosphingolipids was measured by gas chromatography-mass spectrometry of the tetra-0-acetyl methyl glycoside derivatives.
T4 488-704 Sentence denotes Experiments on the precision and accuracy for measurements of [6,6-2H2]hexose in a sample demonstrated that incorporation of 0.2% or more of [6,6-2H2]glucose could be detected with a 95% confidence limit of +/-0.16%.
T5 705-871 Sentence denotes The labeled substrate (35g) was infused into each subject with a 5-g priming dose and the remainder administered at a constant rate of 3 g/hour over a 10-hour period.
T6 872-1059 Sentence denotes During the infusion, the plasma glucose of each subject attained a concentration of about 30% [6,6-2H2]glucose which diminished rapidly after the administration of substrate was complete.
T7 1060-1220 Sentence denotes A concentration of 0.8% [6,6-2H2]glucose was observed in glucosylceramide (GL-la) from plasma of both subjects between 48 and 72 hours after the infusion began.
T8 1221-1362 Sentence denotes The label disappeared from this lipid at a logarithmic rate and 0.2% or less of the molecules were labeled 9 days after the experiment began.
T9 1363-1591 Sentence denotes In contrast to the results with GL-la, the maximum incorporation of [6,6-2H2]hexose into lactosylceramide (galactosyl-(beta1 leads to 4)-glucosylceramide) was 2-fold higher in the Fabry patient (1.6%) than in the control (0.8%).
T10 1592-1887 Sentence denotes The trihexosylceramide (galactosyl-(alpha1 leads to 4)-galactosyl-(beta1 leads to 4)-glucosylceramide, GL-3a) from plasma of the control reached a maximum of 0.4% [6,6-2H2]hexose in both the glucosyl and galactosyl moieties whereas the GL-3a from the Fabry patient was not significantly labeled.
T11 1888-2081 Sentence denotes The maximal labeling of the GL-4a fraction (N-acetyl-galactosaminyl-galactosyl-galactosyl-glucosylceramide) was slightly depressed in the Fabry patient (0.4%) as compared to the control (0.7%).
T12 2082-2223 Sentence denotes Turnover times for the glycosphingolipids of plasma were calculated to be from 4 to 8 days and the turnover rates were from 1 to 6 mumol/day.

GlyCosmos15-GlycoEpitope

Id Subject Object Predicate Lexical cue glycoepitope_id
T1 1452-1468 http://purl.jp/bio/12/glyco/glycan#Glycan_epitope denotes lactosylceramide http://www.glycoepitope.jp/epitopes/EP0078

GlyCosmos15-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 88-103 Disease denotes Fabry's disease MONDO:0010526
T2 266-281 Disease denotes Fabry's disease MONDO:0010526

GlyCosmos15-FMA

Id Subject Object Predicate Lexical cue db_id
T1 44-50 Body_part denotes plasma FMA:62970
T2 219-225 Body_part denotes plasma FMA:62970
T3 897-903 Body_part denotes plasma FMA:62970
T4 1147-1153 Body_part denotes plasma FMA:62970
T5 1707-1713 Body_part denotes plasma FMA:62970
T6 2127-2133 Body_part denotes plasma FMA:62970

NCBITAXON

Id Subject Object Predicate Lexical cue db_id
T1 63-68 OrganismTaxon denotes human 9606
T2 75-82 OrganismTaxon denotes patient 9606
T3 253-260 OrganismTaxon denotes patient 9606
T4 1549-1556 OrganismTaxon denotes patient 9606
T5 1849-1856 OrganismTaxon denotes patient 9606
T6 2032-2039 OrganismTaxon denotes patient 9606

Anatomy-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 44-50 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T2 219-225 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T3 897-903 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T4 1147-1153 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T5 1707-1713 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969
T6 2127-2133 Body_part denotes plasma http://purl.obolibrary.org/obo/UBERON_0001969